InflaRx (IFRX) Profit After Tax (2016 - 2026)
InflaRx (IFRX) posted Profit After Tax of -$6.6 million for Q1 2026, up 45.59% sequentially from -$12.1 million in Q4 2025, and up 26.27% YoY from -$5.2 million in Q1 2025.
InflaRx (IFRX) Profit After Tax (2016 - 2026) Analysis & Trends
InflaRx has reported Profit After Tax for 11 years, with the latest figure at -$6.6 million in Q1 2026.
- Quarterly Profit After Tax rose 26.27% year-over-year to -$6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.5 million (up 11.56% YoY) and the FY2025 annual result came in at -$51.6 million, down 3.33% from the prior year.
- Profit After Tax climbed to -$6.6 million in Q1 2026 per IFRX's latest filing, from -$12.1 million in the prior quarter.
- Over five years, Profit After Tax peaked at $16.4 million in Q2 2025 and troughed at -$11914.8 billion in Q1 2023.
- A 5-year average of -$700.9 billion and a median of -$8.9 million in 2025 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2023: Profit After Tax soared 100.0% in 2022, then plunged 75817607.08% in 2023.
- Over 5 years, Profit After Tax stood at -$18.4 million in 2022, then gained by 6.66% to -$17.2 million in 2023, then surged by 68.47% to -$5.4 million in 2024, then tumbled by 122.51% to -$12.1 million in 2025, then soared by 45.59% to -$6.6 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$6.6 million, -$12.1 million, and -$14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | -12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.57 Mn |
| Dec 31, 2025 | -12.07 Mn |
| Sep 30, 2025 | -14.35 Mn |
| Jun 30, 2025 | 16.45 Mn |
| Mar 31, 2025 | -8.90 Mn |
| Dec 31, 2024 | -5.42 Mn |
| Sep 30, 2024 | -19.25 Mn |
| Jun 30, 2024 | 14.88 Mn |
| Mar 31, 2024 | -10.52 Mn |
| Dec 31, 2023 | -17.20 Mn |
| Sep 30, 2023 | -8.03 Mn |
| Jun 30, 2023 | 8.93 Mn |
| Mar 31, 2023 | -11,914.76 Bn |
| Dec 31, 2022 | -18.43 Mn |
| Sep 30, 2022 | -3.63 Mn |
| Jun 30, 2022 | 5.20 Mn |
| Mar 31, 2022 | -15.72 Mn |
| Dec 31, 2021 | -52,199.42 Bn |
| Sep 30, 2021 | -14.22 Mn |
| Jun 30, 2021 | 19.52 Mn |